Participant flow

PALbociclib CoLlaborative Adjuvant Study · Source last updated 2026-06-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.

   id

   FG000

   title

   Palbociclib Plus Endocrine Therapy (Arm A)

2. description

   Standard adjuvant endocrine therapy for a duration of at least 5 years.

   id

   FG001

   title

   Endocrine Therapy Alone (Arm B)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         23

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Ineligible

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         2896

      2. group Id

         FG001

         num Subjects

         2900

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         2884

      2. group Id

         FG001

         num Subjects

         2877

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         12

      2. group Id

         FG001

         num Subjects

         23

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice